Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroma, Acoustic 1 Neurofibromatosis 2 1 Meningioma 1 Lung Neoplasms 1 Ependymoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 8 X-Rays 6 Specimen Handling 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 5 Biopsy 4 ulixertinib 2 tipifarnib 2 tazemetostat 2 selpercatinib 2 palbociclib 2 olaparib 2 lutetium Lu 177 dotatate 2 larotrectinib 2 ivosidenib 2 erdafitinib 2 ensartinib 2 LY3023414 2 pembrolizumab 1 neratinib 1 cemiplimab 1 brigatinib 1 Watchful Waiting 1 Vincristine 1 Vemurafenib 1 Temozolomide 1 Radiotherapy, Conformal 1 Radiotherapy 1 Radiation 1 Platinum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ependymoma × brigatinib × 90 days × Clear all

NCT04374305 2026-05-06

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡